Out-Licensing Vibegron to Sumitomo Pharma
First written in FY2023. 1 of 3 entries say "Reframed", first in FY2026-H1. Latest entry: 2026-09-29.
No other company in this theme has enough history to compare yet.
- 2026-09-29AdvancedOther Disclosures
「Taiwan Marubeni Pharmaceutical Co., Ltd., a subsidiary of Marubeni Pharmaceuticals Co., Ltd. (head office: Chuo-ku, Tokyo; President and Representative Director: Nishinaka Shigeyuki (西中重行); hereinafter, “Marubeni Pharmaceuticals”), the licensee, began selling the product in Taiwan on 22 September (Taiwanese product name: “Gemtesa”).」
Regarding vibegron, progress has been made through the launch of sales in Taiwan based on the rights in Asia transferred from Sumitomo Pharma to Marubeni Pharmaceuticals. - FY2026-H1Change in licenseeAnnual report
「The counterparty to the agreement has changed from Sumitomo Pharma Co., Ltd. to Marubeni Pharmaceuticals Co., Ltd.」
Under the 2023 licensing agreement for vibegron, the counterparty has changed from Sumitomo Pharma to Marubeni Pharmaceuticals. - FY2023First statedAnnual report
「Vibegron; Sumitomo Pharma Co., Ltd.; Japan; upfront fee, development milestones, sales milestones and royalties at a specified rate; 2023; from the date of execution until the obligation to pay royalties ends.」
A Japanese out-licensing agreement for vibegron was entered into with Sumitomo Pharma in 2023.